Biotech stocks are booming again.
The iShares Nasdaq Biotechnology ETF (IBB) - Get iShares NASDAQ Biotechnology ETF Report closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25. The sector's steep sell off in March and April are a distant memory. Roche's (RHHBY) acquisition of InterMune (ITMN) has put some M&A oomph into biotech stocks.
As you'd expect, biotech stocks are out-performing the S&P 500.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.